Logo do repositório
 
Publicação

Classification of current anticancer immunotherapies

2014-12-30Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorGalluzzi, Lorenzo
dc.contributor.authorVacchelli, Erika
dc.contributor.authorBravo-San Pedro, José-Manuel
dc.contributor.authorBuqué, Aitziber
dc.contributor.authorSenovilla, Laura
dc.contributor.authorBaracco, Elisa Elena
dc.contributor.authorBloy, Norma
dc.contributor.authorCastoldi, Francesca
dc.contributor.authorAbastado, Jean-Pierre
dc.contributor.authorAgostinis, Patrizia
dc.contributor.authorApte, Ron N.
dc.contributor.authorAranda, Fernando
dc.contributor.authorAyyoub, Maha
dc.contributor.authorBeckhove, Philipp
dc.contributor.authorBlay, Jean-Yves
dc.contributor.authorBracci, Laura
dc.contributor.authorCaignard, Anne
dc.contributor.authorCastelli, Chiara
dc.contributor.authorCavallo, Federica
dc.contributor.authorCelis, Estaban
dc.contributor.authorCerundolo, Vincenzo
dc.contributor.authorClayton, Aled
dc.contributor.authorColombo, Mario P.
dc.contributor.authorCoussens, Lisa
dc.contributor.authorDhodapkar, Madhav V.
dc.contributor.authorEggermont, Alexander M.
dc.contributor.authorFearon, Douglas T.
dc.contributor.authorFridman, Wolf H.
dc.contributor.authorFučíková, Jitka
dc.contributor.authorGabrilovich, Dmitry I.
dc.contributor.authorGalon, Jérôme
dc.contributor.authorGarg, Abhishek
dc.contributor.authorGhiringhelli, François
dc.contributor.authorGiaccone, Giuseppe
dc.contributor.authorGilboa, Eli
dc.contributor.authorGnjatic, Sacha
dc.contributor.authorHoos, Axel
dc.contributor.authorHosmalin, Anne
dc.contributor.authorJäger, Dirk
dc.contributor.authorKalinski, Pawel
dc.contributor.authorKärre, Klas
dc.contributor.authorKepp, Oliver
dc.contributor.authorKiessling, Rolf
dc.contributor.authorKirkwood, John M.
dc.contributor.authorKlein, Eva
dc.contributor.authorKnuth, Alexander
dc.contributor.authorLewis, Claire E.
dc.contributor.authorLiblau, Roland
dc.contributor.authorLotze, Michael T.
dc.contributor.authorLugli, Enrico
dc.contributor.authorMach, Jean-Pierre
dc.contributor.authorMattei, Fabrizio
dc.contributor.authorMavilio, Domenico
dc.contributor.authorMelero, Ignacio
dc.contributor.authorMelief, Cornelis J.
dc.contributor.authorMittendorf, Elizabeth A.
dc.contributor.authorMoretta, Lorenzo
dc.contributor.authorOdunsi, Adekunke
dc.contributor.authorOkada, Hideho
dc.contributor.authorPalucka, Anna Karolina
dc.contributor.authorPeter, Marcus E.
dc.contributor.authorPienta, Kenneth J.
dc.contributor.authorPorgador, Angel
dc.contributor.authorPrendergast, George C.
dc.contributor.authorRabinovich, Gabriel A.
dc.contributor.authorRestifo, Nicholas P.
dc.contributor.authorRizvi, Naiyer
dc.contributor.authorSautès-Fridman, Catherine
dc.contributor.authorSchreiber, Hans
dc.contributor.authorSeliger, Barbara
dc.contributor.authorShiku, Hiroshi
dc.contributor.authorSilva-Santos, Bruno
dc.contributor.authorSmyth, Mark J.
dc.contributor.authorSpeiser, Daniel E.
dc.contributor.authorSpisek, Radek
dc.contributor.authorSrivastava, Pramod K.
dc.contributor.authorTalmadge, James E.
dc.contributor.authorTartour, Eric
dc.contributor.authorVan Der Burg, Sjoerd H.
dc.contributor.authorVan Den Eynde, Benoît J.
dc.contributor.authorVile, Richard
dc.contributor.authorWagner, Hermann
dc.contributor.authorWeber, Jeffrey S
dc.contributor.authorWhiteside, Theresa L.
dc.contributor.authorWolchok, Jedd D.
dc.contributor.authorZitvogel, Laurence
dc.contributor.authorZou, Weiping
dc.contributor.authorKroemer, Guido
dc.date.accessioned2021-05-28T12:41:08Z
dc.date.available2021-05-28T12:41:08Z
dc.date.issued2014-12-30
dc.description© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.pt_PT
dc.description.abstractDuring the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationOncotarget. 2014 Dec 30;5(24):12472-12508pt_PT
dc.identifier.doi10.18632/oncotarget.2998pt_PT
dc.identifier.eissn1949-2553
dc.identifier.urihttp://hdl.handle.net/10451/48232
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherImpact Journals, LLCpt_PT
dc.relation.publisherversionhttps://www.oncotarget.com/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAdoptive cell transferpt_PT
dc.subjectCheckpoint blockerspt_PT
dc.subjectDendritic cell-based interventionspt_PT
dc.subjectDNA-based vaccinespt_PT
dc.subjectImmunostimulatory cytokinespt_PT
dc.subjectPeptide-based vaccinespt_PT
dc.subjectOncolytic virusespt_PT
dc.subjectToll-like receptor agonistspt_PT
dc.titleClassification of current anticancer immunotherapiespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage12508pt_PT
oaire.citation.issue24pt_PT
oaire.citation.startPage12472pt_PT
oaire.citation.titleOncotargetpt_PT
oaire.citation.volume5pt_PT
person.familyNameSilva-Santos
person.givenNameBruno
person.identifier.ciencia-idD51E-6517-BE6A
person.identifier.orcid0000-0003-4141-9302
person.identifier.scopus-author-id6505885924
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationf313ff02-41ee-4014-88a1-bd641b6219bf
relation.isAuthorOfPublication.latestForDiscoveryf313ff02-41ee-4014-88a1-bd641b6219bf

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Anticancer_immunotherapies.pdf
Tamanho:
1.36 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais